News Pfizer, Arvinas join SERD club with Veppanu approval Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News Danco fights back after US court curbs abortion pill access In another setback for abortion care in the US, an appeals court has issued an order restricting the distribution of mifepristone through the mail.
News FDA's ODAC delivers one loss, one win for AstraZeneca The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News Axsome breaks new ground in Alzheimer's with Auvelity OK Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
News NICE backs UCB drug as first uncontrolled gMG therapy UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
News Norgine gets first EU approval for WHIM syndrome therapy Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
News Pharvaris plans filings for HAE drug after pivotal trial win Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
